Oxford Therapeutics London
The GLP-1 Legacy
How to Maintain Weight Loss after Ozempic, Wegovy or Mounjaro
The GLP-1 Legacy is a practical and compassionate guide to life after weight-loss injections. Millions of people have found hope and healing through GLP-1 medications, such as Ozempic, Wegovy and Mounjaro. But what comes next? The GLP-1 Legacy is the first comprehensive guide designed specifically for individuals transitioning off weight-loss injections, offering the knowledge, tools and emotional support needed to sustain their transformation for life.
Drawing from psychology, behavioural science and real-world experience, this empowering book helps readers navigate the physical, emotional and identity shifts that occur after stopping medication. It replaces fear with confidence and provides a safety net for anyone afraid of weight regain, loss of control or old habits returning.
Inside the book
– Practical tools to maintain weight loss after GLP-1s
– Strategies to retrain the brain and break food dependence
– How to handle triggers, cravings, social eating and low motivation
– A guide to micro-dosing, tapering and sustainable habit building
– Real-life case studies, including a recurring character “Alice,” who offers wisdom, humour and hard-earned insight
The GLP-1 Legacy is certainly not a diet book. It’s a compassionate, science-backed companion for those ready to write the next chapter of their health story, without shame or fear. Why This Book Now? The GLP-1 revolution has transformed lives, and it’s only just beginning. However, most people will eventually stop taking the medication. They need more than willpower.
The GLP-1 Legacy, Publication date August 2025
The GLP-1 Legacy is the essential guide for navigating the emotional, physical and psychological challenges that follow GLP-1 treatment. As countless users are now learning, weight loss is only half the battle. Maintenance is where the real work begins.
Authors Martin and Marion Shirran have created an essential guide, a roadmap to help patients transition and navigate what comes after the medications stop. While the injections helped them lose the weight, we know it’s their mindset, habits, and strategy going forward that will ensure the weight loss achieved is permanent. The book is overflowing with proven, practical, real-world advice to help them maintain their transformation and thrive. The readers are not starting over; they are moving forward. Throughout the book, readers are additionally introduced to a group of individuals who are in the post-GLP phase, and have successfully navigated the transition.
Award-Winning Programme
The GLP-1 Legacy from Oxford Therapeutics has already piqued the interest of healthcare professionals aware of the importance of ‘wraparound’ care for individuals transitioning from GLP-1 therapy. Many have been seeking a proven behaviour change, diet/exercise programme for their patients, to partner with their prescribing of GLP-1 receptor agonists. It is hoped that this book will fill the void.
Food and Drug Administration
In the United States, the Food and Drug Administration (FDA) has mandated that GLP-1 receptor agonist weight-loss medications be prescribed in conjunction with a behavioural change programme. The FDA’s approach aims to ensure that patients not only lose weight but also adopt healthier lifestyle habits, which is crucial for maintaining their weight loss in the long term. This regulatory stance underscores the necessity of a comprehensive treatment plan, as detailed on the pages of this website.
NICE
Similarly, the National Institute for Health and Care Excellence (NICE) in the United Kingdom advocates a multifaceted approach to weight management. NICE recommends that weight-loss medications be integrated into a comprehensive weight management programme. The guidance from NICE emphasises the importance of addressing obesity through a holistic and sustainable approach, aiming to deliver long-term health benefits and improved quality of life for patients. Marion Shirran, the co-founder of Oxford Therapeutics Ltd, is a NICE stakeholder and a member of the All-Party Parliamentary Group on Obesity.
Oxford Therapeutics
Martin and Marion Shirran, the founders of Oxford Therapeutics, were responsible for developing the upgrade to the traditional Cognitive Behaviour Therapy (CBT) approaches and techniques. It’s known as Tactile Cognitive Behaviour Therapy, or TCBT. “In a single moment, you have elevated CBT from being a completely passive therapy into a useful tactile alternative!” (Dr Theano Kalavana). Academics, including Professor Windy Dryden, of Goldsmiths University London, and the late Professor Philip Zimbardo, of Stanford University, in San Francisco, have endorsed the therapy. Professor Zimbardo wrote the foreword to their recent book regarding TCBT, published by Hay House.
Stakeholder in NICE – National Institute for Health and Care Excellence
Marion Shirran, as a director of Oxford Therapeutics Limited, is a registered Stakeholder in NICE – National Institute for Health and Care Excellence.
All-Party Parliamentary Group on Obesity
Marion is proud to be a member of the All-Party Parliamentary Group on Obesity.
Please visit the contact page for email or telephone details.
